VistaGen Therapeutics (VTGN) TD Cowen 45th Annual Health Care Conference summary

Key innovations and drug class overview

• Introduced a new class of intranasal drugs called pherines, targeting neurocircuitry for rapid, nonsystemic therapeutic effects across multiple indications.

• Five distinct pherine assets have shown positive clinical data, with lead programs in social anxiety disorder, major depressive disorder, and menopausal hot flashes.

• Pherines activate chemosensory neurons in the nasal cavity, leading to targeted brain region effects without systemic exposure or typical side effects.

• Safety profile is highly differentiated: no drug-drug interactions, no sexual side effects, no weight gain, and no abuse liability.

• Each asset is designed for rapid onset and as-needed use, improving patient compliance and quality of life.

Clinical development and trial progress

• Lead asset Fasedienol is in U.S. phase III trials for acute treatment of social anxiety disorder, with two additional phase III readouts expected by year-end.

• PALISADE II phase III study showed statistically significant improvements in anxiety symptoms during public speaking challenges, with strong patient and clinician-reported outcomes.

• Long-term safety data from open-label studies show headache as the most common adverse event (8.7%), with no other treatment-emergent adverse event above 5%.

• Enhanced trial protocols post-pandemic include rigorous in-person training, site surveillance, and audio monitoring to ensure protocol adherence and reduce variability.

• Phase III studies now benefit from normalized clinical environments, reduced attrition, and improved execution compared to pandemic-era trials.

Pipeline expansion and future plans

• Itruvone for major depressive disorder demonstrated rapid onset and positive phase II results; phase IIB is planned for late 2024, pending funding.

• PHADE targets vasomotor symptoms of menopause with a non-hormonal, non-systemic approach, showing significant reduction in hot flash frequency and severity in phase IIa.

• Each pherine is a distinct chemical entity, targeting specific brain regions for different indications, aiming to transform standards of care.

• Future studies will replicate successful endpoints and designs, with shorter durations and subgroup analyses for anxious depression.

• Commercial and partnering opportunities are significant across all three lead indications due to unmet needs and differentiated profiles.